Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
16 Janvier 2024 - 2:00PM
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
company, today announced that CEO Josh Riggs will be presenting a
corporate overview at the upcoming Sequire Investor Summit 2024.
The conference is scheduled for January 23-25, 2024 at the Condado
Vanderbilt Hotel in San Juan, Puerto Rico.
For more information about the Sequire Investor
Summit, including registration details, please visit the official
event website at https://puertorico.srax.com/
About Oncocyte
Oncocyte is a precision diagnostics company. The
Company’s tests are designed to help provide clarity and confidence
to physicians and their patients. VitaGraft™ is a blood-based solid
organ transplantation monitoring test. DetermaIO™ is a gene
expression test that assesses the tumor microenvironment to predict
response to immunotherapies, and the pipeline test DetermaCNI™ is
blood-based monitoring tool for assessing therapeutic efficacy. For
more information, please visit: www.oncocyte.com
DetermaIO™, DetermaCNI™, and VitaGraft™ are
trademarks of Oncocyte Corporation.
About SRAX
SRAX Inc. is a financial technology company that
unlocks data and insights for publicly traded companies. Through
its premier investor intelligence and communications platform,
Sequire, companies can track their investors’ behaviors and trends
and use those insights to engage current and potential investors
across marketing channels. For more information on SRAX, visit
srax.com and mysequire.com
CONTACT
Stephanie PrincePCG Advisory(646)
863-6341sprince@pcgadvisory.com
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024